drugset / Trial / NCT01449279
Pilot Ipilimumab in Stage IV Melanoma Receiving Palliative Radiation Therapy
NaSingle-groupOpen-labelTreatment
Summary
To determine the safety of local palliative radiation therapy used in combination with anti-CTLA-4 immunotherapy.
Timeline
- Start
- 2011-10
- Primary completion
- 2015-12-31
- Completion
- 2016-12-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Ipilimumab | Monoclonal antibody | 3 mg/kg | Intravenous |